Tenaya Therapeutics stock jumps after announcing a research collaboration with Alnylam worth up to $1.13 billion in milestone ...
Agreement Combines Tenaya’s Expertise in Identification and Validation ofGenetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 ...
Tenaya leverages “human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) with high-throughput in vitro screening, imaging analysis, and machine learning algorithms” to identify new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results